Citations

Clear

6273 citation(s) found for "To, Andrew".

Outcomes of Surgical Management in Patients with Stress Urinary Incontinence and/or Neovesicovaginal Fistula after Orthotopic Neobladder Diversion
Bailey, George C., Blackburne, Andrew T. , Ziegelmann, Matthew , Lightner, Deborah J., Blackburne, Andrew, Ziegelmann, Matthew J

Mayo Clinic

Journal of Urology | June 11, 2016 | Volume: 196 | Issue: 5 | Pages: 1478-1483

10.1016/j.juro.2016.06.009 | PMID 27288693 Get It

Perioperative Management of Patients with Diabetes Undergoing Ambulatory Elective Surgery
Coan, Kathryn E., Schlinkert, Andrew B., Beck, Brandon R., Haakinson, Danielle J. , Castro, Janna C. , Schlinkert, Richard T., Cook, Curtiss B.

Mayo Clinic

Journal of Diabetes Science and Technology | June 7, 2016 | Volume: 7 | Issue: 4 | Pages: 983-989

10.1177/193229681300700421 | PMID 23911180 Get It

Objective: The objective was to assess processes of care for patients with diabetes undergoing elective surgery. Methods: A retrospective review of medical records was conducted to determine frequency of perioperative glucose monitoring, changes in glucose control, and treatment of intraoperative hyperglycemia. Results: A total of 268 patients underwent 287 elective procedures. Mean age was 67 years, 63% were men, 97% had type 2 diabetes, and most (57%) were treated with oral hypoglycemic agents. Average perioperative time was approximately 8 h. Mean preoperative hemoglobin A1c was 7.0%; however, this value was checked in only 52% of cases. A glucose measurement was obtained in 89% of cases in the preoperative area and in 87% in the postanesthesia care unit, but in only 33% of cases did a value get checked intraoperatively. Average glucose was 139 mg/dl preoperatively, increasing to 166 mg/dl postoperatively ( p <.001). Glucose levels increased regardless of type of outpatient medical therapy used to treat hyperglycemia, except for those on combination oral agents plus insulin ( p =.06). Conclusions: These data indicate suboptimal documentation of outpatient hemoglobin A1c. Intraoperative glucose monitoring seldom occurred, despite prolonged periods under anesthesia and perioperative deterioration of glycemic control. Standards need to be developed and interventions are needed to enhance management of diabetes patients undergoing elective procedures.
Clinical Inertia during Postoperative Management of Diabetes Mellitus: Relationship between Hyperglycemia and Insulin Therapy Intensification
Coan, Kathryn E., Schlinkert, Andrew B., Beck, Brandon R., Haakinson, Danielle J. , Castro, Janna C. , Apsey, Heidi A., Schlinkert, Richard T., Cook, Curtiss B.

Mayo Clinic

Journal of Diabetes Science and Technology | June 7, 2016 | Volume: 7 | Issue: 4 | Pages: 880-887

10.1177/193229681300700410 | PMID 23911169 Get It

Objective: Our objective was to assess the application of insulin regimens in surgical postoperative patients with diabetes. Methods: A chart review was conducted of patients with diabetes who were hospitalized postoperatively between January 1 and April 30, 2011. Analysis was restricted to patients hospitalized for ≥3 days and excluded cases with an endocrinology consult. Insulin regimens were categorized as “basal plus short acting,” “short acting only,” or “none,” and the pattern of use was evaluated by hyperglycemia severity according to tertiles of both mean glucose and the number of glucose measurements >180 mg/dl. Results: Among cases selected for analysis ( n = 119), examination of changes in insulin use based on tertiles of mean glucose showed that use of basal plus short-acting insulin increased from 10% in the lowest tertile (mean glucose, 120 mg/dl) to 18% in the highest tertile (mean glucose, 198 mg/dl; p < .01); however, 70% of patients in the highest tertile continued to receive short-acting insulin only, with 12% receiving no insulin. Intensification of insulin to a basal plus short-acting regimen was also seen when changes were evaluated by the number of measurements >180 mg/dl ( p < .01), but 70% and 12% of patients in the highest tertile still remained only on short-acting insulin or received no insulin, respectively. Conclusions: Use of basal plus short-acting insulin therapy increased with worsening hyperglycemia, but many cases did not have therapy intensified to the recommended insulin regimen—evidence of clinical inertia. Strategies should be devised to overcome inpatient clinical inertia in the treatment of postoperative patients with diabetes.
Central retinal vein occlusion after plateletpheresis
Roddy, Gavin W. , Kreuter, Justin D. , Koh, Brian D. , Barkmeier, Andrew J.

Mayo Clinic

Transfusion | June 6, 2016 | Volume: 56 | Issue: 6 | Pages: 1258-1258

10.1111/trf.13419 | PMID 27264010 Get It

CSF herpes virus and autoantibody profiles in the evaluation of encephalitis
Linnoila, Jenny, Binnicker, Matthew J. , Majed, Masoud , Linnoila, Jenny J, Klein, Christopher J. , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | June 2, 2016 | Volume: 3 | Issue: 4 | Pages: No page available

10.1212/nxi.0000000000000245 | PMID 27308306 Get It

An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase
Hasassri, M. Earth , Boyce, Thomas G. , Norgan, Andrew P. , Cunningham, Scott A. , Jeraldo, Patricio , Patel, Robin , Banerjee, Ritu , Pogue, Jason M. , Kaye, Keith S. , Jeraldo, Patricio R , Weissman, Scott J. , Patel, Robin , Norgan, Andrew P , Cunningham, Scott A

Mayo Clinic

Antimicrobial Agents and Chemotherapy | May 24, 2016 | Volume: 60 | Issue: 6 | Pages: 3270-3275

10.1128/aac.03118-15 | PMID 27217442 Get It

ABSTRACT We describe a 16-year-old neutropenic patient from the Middle East with bloodstream infection caused by two carbapenemase-producing Escherichia coli isolates that we characterized by whole-genome sequencing. While one displayed meropenem resistance and was bla NDM positive, the other demonstrated meropenem susceptibility yet harbored bla OXA181 (which encodes a bla OXA48 -like enzyme). This report highlights the challenge of laboratory detection of bla OXA48 -like enzymes and the clinical implications of genotypic resistance detection in carbapenemase-producing Enterobacteriaceae .
Health Care Utilization and Direct Medical Costs of Tennis Elbow
Sanders, Thomas L. , Kremers, Hilal Maradit , Bryan, Andrew J., Ransom, Jeanine E. , Morrey, B.F. , Maradit Kremers, Hilal, Morrey, Bernard F, Maradit Kremers, Hilal

Mayo Clinic

Sports Health: A Multidisciplinary Approach | May 23, 2016 | Volume: 8 | Issue: 4 | Pages: 355-358

10.1177/1941738116650389 | PMID 27215568 Get It

Background: Tennis elbow is commonly encountered by physicians, yet little is known about the cost of treating this condition. Hypothesis: The largest cost associated with treating tennis elbow is procedural intervention. Study Design: Descriptive epidemiology study. Level of Evidence: Level 4. Methods: This retrospective population-based study reviewed patients who were treated for new-onset tennis elbow between January 1, 2003 and December 31, 2012. All patients were followed up through their medical and administrative records to identify health care encounters and interventions for tennis elbow. Unit costs for each health service/procedure were adjusted to nationally representative unit costs in 2013 inflation-adjusted dollars. Results: In a cohort of 931 patients who had 2 or more clinical encounters for new-onset lateral epicondylosis during a 12-month period after initial diagnosis, 62% received a median of 3 physical therapy sessions (cost, $100/session) and 40% received a median of 1 steroid injection (cost, $82/injection). Only 4% of patients received surgical intervention with mean costs of $4000. The mean (median) total direct medical cost of services related to lateral epicondylosis for the entire cohort was $660 ($402) per patient over the 1-year period after diagnosis. Patients who continued to be treated conservatively between 6 and 12 months after diagnosis incurred relatively low median costs of $168 per patient. Conclusion: In this cohort, a second encounter with a physician for tennis elbow was a strong predictor of increased treatment cost due to a higher likelihood of specialist referral, use of physical therapy, or treatment with steroid injection. Clinical Relevance: The majority of direct medical spending on tennis elbow occurs within the first 6 months of treatment, and relatively little expense occurs between 6 and 12 months after diagnosis unless a patient undergoes surgical intervention.
Abstract B143: Pharmacogenomic of refractory response to R-CHOP therapy in diffuse large B-cell lymphoma (DLBCL) patients
Breitenstein, Matthew K. , Novak, Anne J. , Thompson, Carrie A. , Olswold, Curtis L., Nowakowski, Grzegorz S. , Ansell, Stephen M. , Weinshilboum, Richard M. , Wang, Liewei , Slager, Susan L. , Maurer, Matthew J. , Farooq, Umar , Link, Brian K. , Habermann, Thomas M. , Feldman, Andrew L. , Witzig, Thomas E. , Weinshilboum, Richard M. , Cerhan, James R.

Mayo Clinic

Molecular Cancer Therapeutics | May 20, 2016 | Volume: 14 | Issue: 12_Supplement_2 | Pages: B143-B143

10.1158/1535-7163.targ-15-b143 Get It

Abstract Background: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy is standard of care for patients with newly diagnosed DLBCL. A majority of patients respond to R-CHOP, however ∼9% will have primary refractory disease and outcomes in these patients are extremely poor. While there is some knowledge of the pharmacogenomic (PGx) determinants of individual agents within R-CHOP, little is known about the PGx determinants of combination therapy. Our study aims to elucidate germline PGx determinants of drug bioavailability and undesirable side chain reactions in DLBCL patients treated with R-CHOP having potential to influence refractory disease. Methods: Newly diagnosed, DLBCL patients treated with R-CHOP between 2002 and 2012 with germline DNA and genotyping data were selected from the Molecular Epidemiology Resource within the Iowa/Mayo Lymphoma SPORE. Refractory disease was defined as either i) a best response of stable or progressive disease or ii) progressive disease by the end of the planned number of cycles of R-CHOP. PGx candidates within known pharmacokinetics and pharmacodynamics (PD) pathways for 11 genes (1,040 single nucleotide polymorphisms (SNPs)) were selected for study (CPT 2012;92(4):414-7). Odds ratios (ORs) and 95% confidence intervals (CI) were used to estimate the association of SNPs with refractory disease, controlling for age, gender, and age-adjusted International Prognostic Index. Results: The median age at diagnosis of 424 of DLBCL patients treated with R-CHOP was 62 years (range 18-92); 45.7% were female; and 58.4% had Ann Arbor Stage III-IV. By the end of initial therapy 40 patients had primary refractory disease. Of the 1,040 SNPs evaluated, 120 (12%) were significantly associated with refractory disease at the 5% significance threshold suggesting novel associations with drug metabolism. The top SNP from each PGx candidate gene are shown in Table, with ALDH5A1 and CYP2B6 showing the most significant associations. Conclusions: While needing replication, we identified associations within two PGx candidate genes that are potentially functionally related to cyclophosphamide PD: alleles within CYP2B6 may have relevance in R-CHOP outcomes due to potential competition with other drug metabolizing enzymes shared with prednisone and vincristine biotransformation in the liver, and alleles withinALDH5A1 may impact a deactivating side chain reaction in B lymphocytes. Table: R-CHOP PGx candidates with known side chain reactionsPGx candidaten SNPsTop SNPChrOR* (95% CI)P-valueMAFABCB1365rs3480093571.86 (1.14 – 3.04)1.32E-020.29ADH1A32rs122996841.66 (0.60 - 4.53)3.27E-010.038ALDH3A116rs2228100171.26 (0.71 - 2.22)4.28E-010.24ALDH5A1192rs946103466.30 (2.43 - 16.4)1.55E-040.030CBR110rs2835266212.10 (0.90 - 4.89)8.76E-020.052CBR356rs45527331212.12 (0.91 - 4.98)8.29E-020.050CYP2B6107rs1038376192.38 (1.44 - 3.94)7.74E-040.27CYP3A421rs2898858372.32 (0.80 - 6.78)1.23E-010.028CYP3A531rs778032871.69 (0.68 - 4.16)2.57E-010.054SLC22A16193rs11217403561.80 (1.06 - 3.03)2.78E-020.21SOD116rs1041740211.35 (0.83 - 2.19)2.26E-010.32Chr=chromosome, MAF=minor allele frequency, *Adjusted for age, sex, and age-adjusted International Prognostic Index Citation Format: Matthew K. Breitenstein, Susan L. Slager, Anne J. Novak, Matthew J. Maurer, Carrie A. Thompson, Umar Farooq, Brian K. Link, Thomas M. Habermann, Curtis L. Olswold, Andrew L. Feldman, Grzegorz S. Nowakowski, Stephen M. Ansell, Thomas E. Witzig, Richard M. Weinshilboum, Liewei Wang, James R. Cerhan. Pharmacogenomic of refractory response to R-CHOP therapy in diffuse large B-cell lymphoma (DLBCL) patients. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B143.